Agreements

Date: 2017-07-27

Type of information: Termination of an agreement

Compound: novel drug candidates for an undisclosed activated kinase target

Company: Alexion Pharmaceuticals (USA - CT) Blueprint Medicines (USA - MA)

Therapeutic area: Rare diseases - Genetic diseases

Type agreement: R&D - development - commercialisation

Action mechanism:

Disease: undisclosed rare genetic disease

Details:

• On March 3, 2015, Blueprint Medicines announced a strategic collaboration with Alexion to discover, develop and commercialize novel drug candidates for an undisclosed activated kinase target, which is the cause of a rare genetic disease. Blueprint Medicines will apply its kinase-focused drug discovery platform to identify and optimize drug candidates and will conduct all research activities prior to the filing of an Investigational New Drug (IND) application with the FDA. Alexion will be responsible for the development and commercialization of these Blueprint Medicines' drug candidates under the collaboration.

Financial terms:

Under the terms of the agreement, Blueprint Medicines will receive an upfront payment of $15 million and will be reimbursed for all research expenses. Blueprint Medicines is eligible to receive over $250 million in payments upon the successful achievement of pre-specified preclinical, clinical, regulatory and commercial milestones. In addition, Blueprint Medicines will be eligible to receive royalty payments following the commercialization of the product.

Latest news:

• On July 27, 2017, Alexion Pharmaceuticals announced that the company is redefining its R&D strategy to create greater efficiency and focus on its expertise in complement biology and core therapeutic areas of hematology, nephrology, neurology, and metabolic disorders. To optimize and align R&D investments and development efforts with the Company's redefined strategy, Alexion is de-prioritizing the ALXN1101 (cPMP replacement therapy) and ALXN6000 (samalizumab) clinical development programs and will seek to out-license these assets. Alexion is also discontinuing its preclinical programs with mRNA therapies as well as other preclinical programs that are outside of the complement franchise, and is therefore terminating its partnerships with Moderna Therapeutics, Blueprint Medicines and Arbutus Biopharma.